Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

PYLARIFY® PET/CT eller PET/MRI hos menn med gunstig middels risiko (FIR) prostatakreft (MIRROR)

12. november 2026 oppdatert av: Lantheus Medical Imaging

En fase 4 åpen multisenterstudie av PYLARIFY® PET/CT eller PET/MRI hos menn med nylig diagnostisert gunstig middels risiko (FIR) prostatakreft

The purpose of this study is to learn whether PYLARIFY PET imaging (study scan) can safely and accurately detect the presence or absence of prostate cancer growing beyond the prostate gland in men with favorable intermediate risk prostate cancer.

Participants will receive a single dose of PYLARIFY injection followed by a single whole-body PET/CT or PET/MRI scan acquired at 1 to 2 hours after PYLARIFY injection. Participants with positive study scan results that are suspicious for prostate cancer outside of the prostate gland may be asked to undergo additional diagnostic test(s) and/or recommend certain treatment(s) for prostate cancer within 2 to 90 days after the study scan. Participants will be monitored for up to 12 months to collecting information about treatment they receive for prostate cancer and results of regular PSA blood draws if ordered by doctors for up to 12 months after the study scan.

Studieoversikt

Status

Fullført

Forhold

Studietype

Intervensjonell

Registrering (Faktiske)

279

Fase

  • Fase 4

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

    • Alabama
      • Birmingham, Alabama, Forente stater, 35249
        • University of Alabama at Birmingham
    • California
      • Irvine, California, Forente stater, 92618
        • Hoag Cancer Center
      • Los Angeles, California, Forente stater, 90048
        • Tower Urology
      • San Francisco, California, Forente stater, 94158
        • University of California San Francisco
    • Georgia
      • Atlanta, Georgia, Forente stater, 30322
        • Emory University
    • Iowa
      • Iowa City, Iowa, Forente stater, 52242
        • University of Iowa Health Care
    • Maryland
      • Baltimore, Maryland, Forente stater, 21205
        • Johns Hopkins University
    • Massachusetts
      • Boston, Massachusetts, Forente stater, 02114
        • Massachusetts General Hospital
    • Michigan
      • Detroit, Michigan, Forente stater, 48201
        • Karmanos Cancer Institute Wayne State University
      • Grand Rapids, Michigan, Forente stater, 49503
        • BAMF Health
    • Missouri
      • St Louis, Missouri, Forente stater, 63110
        • Washington University School of Medicine
    • Ohio
      • Cleveland, Ohio, Forente stater, 44195
        • Cleveland Clinic
    • Oregon
      • Portland, Oregon, Forente stater, 97239
        • Oregon Health & Science University
    • Utah
      • Salt Lake City, Utah, Forente stater, 84112
        • Huntsman Cancer Institute University of Utah

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Mann

Beskrivelse

Inclusion Criteria:

  1. Patients must have the ability to understand and sign an approved informed consent form (ICF)

  2. Patients must have the ability to understand and comply with all protocol requirements

  3. Patients must be ≥ 18 years of age

  4. Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2

  5. Patients with life expectancy of at least 13 months as determined by the investigator

  6. Patients must have confirmed favorable intermediate risk (FIR) adenocarcinoma of the prostate per 2023 NCCN guidelines. FIR risk group confirmation includes all the following:

    • 1 intermediate risk factor (cT2b-cT2c or ISUP Grade Group 2 or PSA 10-20 ng/mL)
    • ISUP Grade Group 1 or 2
    • <50% biopsy cores positive (e.g., <6 of 12 cores)

Note: Date of the prostate biopsy should be no sooner that 2 weeks and no later than 3 months prior to PYLARIFY PET imaging

Exclusion Criteria:

  1. Patients administered any high energy (>300 KeV) gamma-emitting radioisotope within 5 physical half-lives prior to Day 1 (PYLARIFY imaging)
  2. Previous Prostate cancer treatment including radiation, androgen deprivation therapy, brachytherapy, surgery, prostate ablation, hormonal therapies or investigational therapy
  3. Known hypersensitivity to the components of PYLARIFY or its analogs
  4. Patients with any medical condition or other circumstances that, in the opinion of the investigator, compromise the safety or compliance of the subject to produce reliable data or complete the study
  5. Patients who have any radiographic evidence of T3, N1 or M1 disease on SOC imaging (if performed)

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Diagnostisk
  • Tildeling: N/A
  • Intervensjonsmodell: Enkeltgruppeoppdrag
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: PYLARIFY PET

Participants will receive a single dose of 333 MBq (9 mCi) [296 MBq-370 MBq (8 mCi - 10 mCi)] PYLARIFY injection followed by a single whole-body PET/CT or PET/MRI scan acquired at 1 to 2 hours post-dosing

Andre navn:
  • PYLARIFY
  • 18F-DCFPyL

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Detection rate
Tidsramme: Day 1

The proportion of participants with prostate cancer in whom PYLARIFY PET detected previously occult intraprostatic ISUP grade ≥3 lesions as assessed by pathology, or in whom PYLARIFY PET detected the presence of either/or extraprostatic extension, seminal vesicle invasion, regional lymph node involvement, distant metastases, divided by the number of subjects who undergo a PYLARIFY PET scan

Day 1

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Antall deltakere med uønskede hendelser
Tidsramme: Dag 1
Dag 1
Change in intended patient clinical management
Tidsramme: Day 30

Intended medical management plan before and after PYLARIFY PET imaging

Day 30
True detection rate
Tidsramme: Day 1

The percentage of participants with at least one true positive lesion identified on PYLARIFY PET imaging and confirmed by the truth standard. This measure includes patients in whom PYLARIFY PET detected previously occult intraprostatic ISUP grade ≥3 lesions as confirmed by pathology; or patients in whom PYLARIFY PET detected the presence of either/or extraprostatic extension, seminal vesicle invasion, regional lymph node involvement, distant metastases as assessed by central readers and verified by the standard of truth.

Day 1
Correct localization rate
Tidsramme: up to day 90

The percentage of participants for whom there is a one-to-one correspondence on the same side between the location of at least one lesion outside of prostate capsule (extraprostatic extension, seminal vesicle invasion, pelvic lymph nodes, extrapelvic lymph nodes, extrapelvic bone or extrapelvic soft tissue lesion(s) identified on PYLARIFY PET/CT or PET/MR and the standard of truth.

up to day 90
Positive predictive value of PYLARIFY
Tidsramme: up to day 90

The percentage of participants who undergo PYLARIFY PET imaging that identifies a lesion or lesions outside of the prostate capsule and have an established standard of truth. Positive predictive value does not require a one-to-one correspondence by lesion location but requires that the lesion and standard of truth be within the same anatomic region, including prostatic, pelvic, extra-pelvic or distant lesions.

up to day 90
Sensitivity of PYLARIFY
Tidsramme: up to day 90

Sensitivity at the patient level for patients who undergo prostate surgery for prostate and with pelvic lymph nodes removal.

up to day 90
Specificity of PYLARIFY
Tidsramme: up to day 90

Specificity at the patient level for patients who undergo prostate surgery for prostate and with pelvic lymph nodes removal.

up to day 90
Negative predictive value of PYLARIFY
Tidsramme: up to day 90

Negative predictive value at the patient level for patients who undergo prostate surgery for prostate and with pelvic lymph nodes removal.

up to day 90

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

8. februar 2024

Primær fullføring (Faktiske)

28. august 2026

Studiet fullført (Faktiske)

28. august 2026

Datoer for studieregistrering

Først innsendt

3. oktober 2023

Først innsendt som oppfylte QC-kriteriene

3. oktober 2023

Først lagt ut (Faktiske)

10. oktober 2023

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

17. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

12. november 2026

Sist bekreftet

1. september 2025

Mer informasjon

Begreper knyttet til denne studien

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere